SCHEMBL6532632

SCHEMBL6532632

O=c1[nH]c2nccc(NC3CCN(Cc4ccccc4)CC3)c2c2ccccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 4/20 0.53
ROCK1 Q13464 2/20 0.53
JAK1 P23458 1/20 0.52
AURKA O14965 4/20 0.51
KDM4E B2RXH2 1/20 0.50
GAA P10253 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
MAPK1 P28482 1/20 0.48
AURKB Q96GD4 2/20 0.48
ACHE P22303 1/20 0.47
DRD2 P14416 1/20 0.47
DRD4 P21917 1/20 0.47
DRD3 P35462 1/20 0.47
CCR2 P41597 1/20 0.47
MCHR1 Q99705 1/20 0.46
PARP14 Q460N5 1/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6526955 0.84 AURKA (0.47) ROCK2ROCK1AURKAKDM4EAURKB
SCHEMBL6531373 0.83 GRIN2B (0.49) AURKAHRH3KMT2AMEN1AURKB
SCHEMBL6521959 0.82 AURKA (0.51) AURKAAURKB
SCHEMBL6530953 0.82 AURKA (0.45) AURKAAURKB
SCHEMBL6519751 0.81 AURKA (0.44) AURKAAURKBDRD4
SCHEMBL6522996 0.81 PARP14 (0.54) ROCK2ROCK1AURKAHRH3ACHE
SCHEMBL6521481 0.80 AURKA (0.46) ROCK2ROCK1AURKAAURKB
SCHEMBL6530755 0.80 ALDH1A1 (0.49) AURKAKDM4EGAAMAPK1AURKB
SCHEMBL6522039 0.80 AURKA (0.50) AURKAAURKB
SCHEMBL6522692 0.79 AURKA (0.56) ROCK2ROCK1JAK1AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
US-8735584-B2 Protein kinase inhibitors and use thereof MERCK PATENT GMBH (DE) 2014-05-27 US disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
EP-2254889-B1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2012-12-19 EP disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK PATENT GMBH (DE) 2011-03-03 US disclosed
WO-2009108670-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MERCK SERONO S.A. (CH) 2009-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053906-A1 PROTEIN KINASE INHIBITORS AND USE THEREOF MAP4K2, MAP3K20, MAP4K1 ROCK2 736/4885ROCK1 761/4885JAK1 239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.